SiBone (NASDAQ:SIBN) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of SiBone (NASDAQ:SIBN) from a hold rating to a buy rating in a report issued on Saturday,Wall Street Zen reports.

Other equities research analysts also recently issued reports about the company. Truist Financial raised their price target on SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Citigroup reiterated a “market outperform” rating on shares of SiBone in a report on Tuesday. UBS Group boosted their price target on SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 3rd. TD Cowen increased their price objective on SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. Finally, Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.00.

SiBone Trading Down 0.1%

NASDAQ SIBN opened at $24.24 on Friday. The company has a current ratio of 7.58, a quick ratio of 7.55 and a debt-to-equity ratio of 0.19. SiBone has a 1-year low of $11.48 and a 1-year high of $25.92. The firm’s fifty day simple moving average is $19.81 and its 200-day simple moving average is $16.59. The company has a market capitalization of $1.09 billion, a PE ratio of -78.19 and a beta of 0.64.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. The firm had revenue of $55.70 million during the quarter, compared to analysts’ expectations of $55.31 million. As a group, sell-side analysts anticipate that SiBone will post -0.34 earnings per share for the current fiscal year.

Insider Buying and Selling at SiBone

In other SiBone news, Director Jeffrey Dunn sold 20,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $20.89, for a total value of $417,800.00. Following the completion of the sale, the director owned 16,057 shares of the company’s stock, valued at $335,430.73. The trade was a 55.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Laura Francis sold 75,000 shares of the business’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $25.30, for a total value of $1,897,500.00. Following the completion of the sale, the chief executive officer directly owned 304,256 shares of the company’s stock, valued at $7,697,676.80. This represents a 19.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 372,859 shares of company stock valued at $8,034,168. Company insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SIBN. First Light Asset Management LLC raised its stake in shares of SiBone by 51.8% in the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after purchasing an additional 2,774,795 shares in the last quarter. Granahan Investment Management LLC lifted its position in SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after purchasing an additional 858,942 shares during the period. Paradigm Capital Management Inc. NY boosted its stake in SiBone by 113.3% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after buying an additional 598,300 shares in the last quarter. Renaissance Technologies LLC boosted its stake in SiBone by 101.6% during the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock worth $5,969,000 after buying an additional 238,219 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in SiBone by 41.8% during the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after buying an additional 182,465 shares in the last quarter. 98.11% of the stock is owned by institutional investors.

More SiBone News

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
• Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
• Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
• Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.